398 related articles for article (PubMed ID: 25153594)
41. Elucidation of the Genomic-Epigenomic Interaction Landscape of Aggressive Prostate Cancer.
Kumar Mamidi TK; Wu J; Hicks C
Biomed Res Int; 2021; 2021():6641429. PubMed ID: 33511206
[TBL] [Abstract][Full Text] [Related]
42. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor.
Xin L; Teitell MA; Lawson DA; Kwon A; Mellinghoff IK; Witte ON
Proc Natl Acad Sci U S A; 2006 May; 103(20):7789-94. PubMed ID: 16682621
[TBL] [Abstract][Full Text] [Related]
43. Identification of androgen response-related lncRNAs in prostate cancer.
Karthikeyan SK; Xu N; Ferguson Rd JE; Rais-Bahrami S; Qin ZS; Manne U; Netto GJ; S Chandrashekar D; Varambally S
Prostate; 2023 May; 83(6):590-601. PubMed ID: 36760203
[TBL] [Abstract][Full Text] [Related]
44. The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management.
Ramnarine VR; Kobelev M; Gibb EA; Nouri M; Lin D; Wang Y; Buttyan R; Davicioni E; Zoubeidi A; Collins CC
Eur Urol; 2019 Nov; 76(5):546-559. PubMed ID: 31445843
[TBL] [Abstract][Full Text] [Related]
45. Discovery of a novel long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth.
Ta HQ; Whitworth H; Yin Y; Conaway M; Frierson HF; Campbell MJ; Raj GV; Gioeli D
Mol Cancer; 2019 Jun; 18(1):113. PubMed ID: 31253147
[TBL] [Abstract][Full Text] [Related]
46. Construction of a lncRNA-PCG bipartite network and identification of cancer-related lncRNAs: a case study in prostate cancer.
Liu Y; Zhang R; Qiu F; Li K; Zhou Y; Shang D; Xu Y
Mol Biosyst; 2015 Feb; 11(2):384-93. PubMed ID: 25385343
[TBL] [Abstract][Full Text] [Related]
47. Signaling through estrogen receptors modulates long non-coding RNAs in prostate cancer.
Nanni S; Bacci L; Aiello A; Re A; Salis C; Grassi C; Pontecorvi A; Gaetano C; Farsetti A
Mol Cell Endocrinol; 2020 Jul; 511():110864. PubMed ID: 32413384
[TBL] [Abstract][Full Text] [Related]
48. IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway.
Zhang L; Qi M; Feng T; Hu J; Wang L; Li X; Gao W; Liu H; Jiao M; Wu Z; Bai X; Bie Y; Liu L; Han B
Neoplasia; 2018 Feb; 20(2):207-217. PubMed ID: 29331887
[TBL] [Abstract][Full Text] [Related]
49. Targeting long non-coding RNAs in cancers: progress and prospects.
Li CH; Chen Y
Int J Biochem Cell Biol; 2013 Aug; 45(8):1895-910. PubMed ID: 23748105
[TBL] [Abstract][Full Text] [Related]
50. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.
Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C
Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780
[TBL] [Abstract][Full Text] [Related]
51. Oncogenic non-coding RNA NEAT1 promotes the prostate cancer cell growth through the SRC3/IGF1R/AKT pathway.
Xiong W; Huang C; Deng H; Jian C; Zen C; Ye K; Zhong Z; Zhao X; Zhu L
Int J Biochem Cell Biol; 2018 Jan; 94():125-132. PubMed ID: 29225160
[TBL] [Abstract][Full Text] [Related]
52. Androgen-Responsive Oncogenic lncRNA RP11-1023L17.1 Enhances c-Myc Protein Stability in Prostate Cancer.
Huang W; Chen Q; Lu Y; Kong Z; Wan X; Huang Y; Qiu M; Li Y
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293081
[TBL] [Abstract][Full Text] [Related]
53. Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry.
Yuan J; Kensler KH; Hu Z; Zhang Y; Zhang T; Jiang J; Xu M; Pan Y; Long M; Montone KT; Tanyi JL; Fan Y; Zhang R; Hu X; Rebbeck TR; Zhang L
PLoS Genet; 2020 Feb; 16(2):e1008641. PubMed ID: 32059012
[TBL] [Abstract][Full Text] [Related]
54. Long non-coding RNA SNHG6 is upregulated in prostate cancer and predicts poor prognosis.
Yan Y; Chen Z; Xiao Y; Wang X; Qian K
Mol Biol Rep; 2019 Jun; 46(3):2771-2778. PubMed ID: 30911973
[TBL] [Abstract][Full Text] [Related]
55. New insights into prostate cancer stem cells.
Chen X; Rycaj K; Liu X; Tang DG
Cell Cycle; 2013 Feb; 12(4):579-86. PubMed ID: 23370446
[TBL] [Abstract][Full Text] [Related]
56. Pathological bases and clinical impact of long noncoding RNAs in prostate cancer: a new budding star.
Xu T; Lin CM; Cheng SQ; Min J; Li L; Meng XM; Huang C; Zhang L; Deng ZY; Li J
Mol Cancer; 2018 Jul; 17(1):103. PubMed ID: 30037351
[TBL] [Abstract][Full Text] [Related]
57. TIP5 primes prostate luminal cells for the oncogenic transformation mediated by
Pietrzak K; Kuzyakiv R; Simon R; Bolis M; Bär D; Aprigliano R; Theurillat JP; Sauter G; Santoro R
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3637-3647. PubMed ID: 32024754
[TBL] [Abstract][Full Text] [Related]
58. Updated review on analysis of long non-coding RNAs as emerging diagnostic and therapeutic targets in prostate cancers.
Ke Z; Hu X; Liu Y; Shen D; Khan MI; Xiao J
Crit Rev Oncol Hematol; 2024 Apr; 196():104275. PubMed ID: 38302050
[TBL] [Abstract][Full Text] [Related]
59. eRNAs and Superenhancer lncRNAs Are Functional in Human Prostate Cancer.
Zhang X; Pang P; Jiang M; Cao Q; Li H; Xu Y; Li Y; Chen X; Han J
Dis Markers; 2020; 2020():8847986. PubMed ID: 33029258
[TBL] [Abstract][Full Text] [Related]
60. Transcriptional landscape of PTEN loss in primary prostate cancer.
Imada EL; Sanchez DF; Dinalankara W; Vidotto T; Ebot EM; Tyekucheva S; Franco GR; Mucci LA; Loda M; Schaeffer EM; Lotan T; Marchionni L
BMC Cancer; 2021 Jul; 21(1):856. PubMed ID: 34311724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
